Covered recipient · General Payments record
LAURA ALSINA-SANCHEZ
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
General Payments · PY2019–2025
$2,936.15
- Reported across 142 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $332.69 | 16 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Biogen, Inc. | $72.55 | 4 |
| Amgen Inc. | $54.59 | 3 |
| SHIELD THERAPEUTICS INC | $53.38 | 2 |
| MILLICENT US INC | $38.15 | 2 |
| Astellas Pharma US Inc | $33.37 | 1 |
| MAYNE PHARMA COMMERCIAL LLC | $30.96 | 1 |
| Sumitomo Pharma America, Inc. | $19.81 | 1 |
| Ethicon US, LLC | $15.54 | 1 |
| Exeltis, USA Inc. | $14.34 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $19.66 | 07/24/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228390758 | CMS |
| Amgen Inc. | $18.08 | 09/24/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228390760 | CMS |
| Amgen Inc. | $16.85 | 11/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228390762 | CMS |
| Astellas Pharma US Inc | $33.37 | 09/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238678065 | CMS |
| Biogen, Inc. | $14.35 | 03/31/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1208489253 | CMS |
| Biogen, Inc. | $17.59 | 08/28/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1208385088 | CMS |
| Biogen, Inc. | $21.47 | 09/30/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1208327625 | CMS |
| Biogen, Inc. | $19.14 | 12/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1208492562 | CMS |
| Ethicon US, LLC | $15.54 | 02/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1173841970 | CMS |
| Exeltis, USA Inc. | $14.34 | 04/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1218184718 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $30.96 | 03/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1254273920 | CMS |
| MILLICENT US INC | $18.64 | 03/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1235191035 | CMS |
| MILLICENT US INC | $19.51 | 05/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1235191037 | CMS |
| SHIELD THERAPEUTICS INC | $22.26 | 05/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1249614708 | CMS |
| SHIELD THERAPEUTICS INC | $31.12 | 12/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1249633102 | CMS |
| Sumitomo Pharma America, Inc. | $19.81 | 04/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1176595989 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.